Glycosylation and epitope mapping of the 5T4 glycoprotein oncofoetal antigen. 2002

David M Shaw, and Andrew M Woods, and Kevin A Myers, and Caroline Westwater, and Veena Rahi-Saund, and Michael J Davies, and David V Renouf, and Elizabeth F Hounsell, and Peter L Stern
CRC Immunology Group, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK.

The human 5T4 oncofoetal antigen is a focus for development of several antibody-directed therapies on the basis of the murine monoclonal antibody against 5T4 (mAb5T4), which recognizes a conformational epitope. 5T4 molecules are highly N-glycosylated transmembrane glycoproteins whose extracellular domain contains two regions of leucine-rich repeats (LRRs) and associated flanking regions, separated by an intervening hydrophilic sequence. Using a series of deletion and mutated cDNA constructs as well as chimaeras with the murine homologue, we have mapped the mAb5T4 epitope to the more membrane-proximal LRR2 or its flanking region. Analysis of the glycosylation of the seven consensus Asp-Xaa-Ser/Thr sites was consistent with all of the sites being glycosylated. A combination of two high-mannose chains (predominantly octasaccharide) and five mostly sialylated bi-, tri- and tetra-antennary complex chains with minor quantities of core fucose were detected. The two glycosylation sites, which are the most likely to have predominantly high-mannose chains, are in the only two regions that show significant differences between the human and the 81% identical mouse sequence. A site-directed mutation, which abolished glycosylation at one of these sites (position 192), did not alter antigenicity. The other, which is nearest to the N-terminus in the human, has an Asn-Leu-Thr to Asn-Leu-Leu conversion in the mouse, so cannot be glycosylated in the latter species. The large complex glycosylation at the other sites is likely to influence the antigenicity and tertiary structure generating the 5T4 epitope.

UI MeSH Term Description Entries
D008562 Membrane Glycoproteins Glycoproteins found on the membrane or surface of cells. Cell Surface Glycoproteins,Surface Glycoproteins,Cell Surface Glycoprotein,Membrane Glycoprotein,Surface Glycoprotein,Glycoprotein, Cell Surface,Glycoprotein, Membrane,Glycoprotein, Surface,Glycoproteins, Cell Surface,Glycoproteins, Membrane,Glycoproteins, Surface,Surface Glycoprotein, Cell,Surface Glycoproteins, Cell
D009005 Monosaccharides Single chain carbohydrates that are the most basic units of CARBOHYDRATES. They are typically colorless crystalline substances with a sweet taste and have the same general formula CnH2nOn. Monosaccharide,Simple Sugar,Simple Sugars,Sugar, Simple,Sugars, Simple
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D009844 Oligosaccharides Carbohydrates consisting of between two (DISACCHARIDES) and ten MONOSACCHARIDES connected by either an alpha- or beta-glycosidic link. They are found throughout nature in both the free and bound form. Oligosaccharide
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D002241 Carbohydrates A class of organic compounds composed of carbon, hydrogen, and oxygen in a ratio of Cn(H2O)n. The largest class of organic compounds, including STARCH; GLYCOGEN; CELLULOSE; POLYSACCHARIDES; and simple MONOSACCHARIDES. Carbohydrate
D002469 Cell Separation Techniques for separating distinct populations of cells. Cell Isolation,Cell Segregation,Isolation, Cell,Cell Isolations,Cell Segregations,Cell Separations,Isolations, Cell,Segregation, Cell,Segregations, Cell,Separation, Cell,Separations, Cell
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D003001 Cloning, Molecular The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells. Molecular Cloning
D004591 Electrophoresis, Polyacrylamide Gel Electrophoresis in which a polyacrylamide gel is used as the diffusion medium. Polyacrylamide Gel Electrophoresis,SDS-PAGE,Sodium Dodecyl Sulfate-PAGE,Gel Electrophoresis, Polyacrylamide,SDS PAGE,Sodium Dodecyl Sulfate PAGE,Sodium Dodecyl Sulfate-PAGEs

Related Publications

David M Shaw, and Andrew M Woods, and Kevin A Myers, and Caroline Westwater, and Veena Rahi-Saund, and Michael J Davies, and David V Renouf, and Elizabeth F Hounsell, and Peter L Stern
December 2014, Seminars in cancer biology,
David M Shaw, and Andrew M Woods, and Kevin A Myers, and Caroline Westwater, and Veena Rahi-Saund, and Michael J Davies, and David V Renouf, and Elizabeth F Hounsell, and Peter L Stern
November 2012, Journal of cell science,
David M Shaw, and Andrew M Woods, and Kevin A Myers, and Caroline Westwater, and Veena Rahi-Saund, and Michael J Davies, and David V Renouf, and Elizabeth F Hounsell, and Peter L Stern
August 2012, Lung cancer (Amsterdam, Netherlands),
David M Shaw, and Andrew M Woods, and Kevin A Myers, and Caroline Westwater, and Veena Rahi-Saund, and Michael J Davies, and David V Renouf, and Elizabeth F Hounsell, and Peter L Stern
July 2017, Oncotarget,
David M Shaw, and Andrew M Woods, and Kevin A Myers, and Caroline Westwater, and Veena Rahi-Saund, and Michael J Davies, and David V Renouf, and Elizabeth F Hounsell, and Peter L Stern
April 2017, Cancer immunology, immunotherapy : CII,
David M Shaw, and Andrew M Woods, and Kevin A Myers, and Caroline Westwater, and Veena Rahi-Saund, and Michael J Davies, and David V Renouf, and Elizabeth F Hounsell, and Peter L Stern
July 2012, Cancer immunology, immunotherapy : CII,
David M Shaw, and Andrew M Woods, and Kevin A Myers, and Caroline Westwater, and Veena Rahi-Saund, and Michael J Davies, and David V Renouf, and Elizabeth F Hounsell, and Peter L Stern
August 1995, Journal of cell science,
David M Shaw, and Andrew M Woods, and Kevin A Myers, and Caroline Westwater, and Veena Rahi-Saund, and Michael J Davies, and David V Renouf, and Elizabeth F Hounsell, and Peter L Stern
January 2001, Oral oncology,
David M Shaw, and Andrew M Woods, and Kevin A Myers, and Caroline Westwater, and Veena Rahi-Saund, and Michael J Davies, and David V Renouf, and Elizabeth F Hounsell, and Peter L Stern
December 2000, Biochimica et biophysica acta,
David M Shaw, and Andrew M Woods, and Kevin A Myers, and Caroline Westwater, and Veena Rahi-Saund, and Michael J Davies, and David V Renouf, and Elizabeth F Hounsell, and Peter L Stern
February 2007, Cancer immunology, immunotherapy : CII,
Copied contents to your clipboard!